The DOI matches its Crossref record; 235 of the 235 references it cites were found in a registry or an index.
Extended-Spectrum β-Lactamases: a Clinical Update
Open accessAbstract
SUMMARY: Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by clavulanic acid. Typically, they derive from genes for TEM-1, TEM-2, or SHV-1 by mutations that alter the amino acid configuration around the active site of these β-lactamases. This extends the spectrum of β-lactam antibiotics susceptible to hydrolysis by these enzymes. An increasing number of ESBLs not of TEM or SHV lineage have recently been described. The presence of ESBLs carries tremendous clinical significance. The ESBLs are frequently plasmid encoded. Plasmids responsible for ESBL production frequently carry genes encoding resistance to other drug classes (for example, aminoglycosides). Therefore, antibiotic options in the treatment of ESBL-producing organisms are extremely limited. Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported. ESBL-producing organisms may appear susceptible to some extended-spectrum cephalosporins. However, treatment with such antibiotics has been associated with high failure rates. There is substantial debate as to the optimal method to prevent this occurrence. It has been proposed that cephalosporin breakpoints for the Enterobacteriaceae should be altered so that the need for ESBL detection would be obviated. At present, however, organizations such as the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) provide guidelines for the detection of ESBLs in klebsiellae and Escherichia coli. In common to all ESBL detection methods is the general principle that the activity of extended-spectrum cephalosporins against ESBL-producing organisms will be enhanced by the presence of clavulanic acid. ESBLs represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P. aeruginosa is highly resistant to various antibiotics including penicillin, cephalosporin, and aztreonam by producing extended-spectrum β-lactamases (ESBLs).246,247”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [246]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–235 of 235
Decré, D., Gachot, B., Lucet, J. C., Arlet, G., Bergogne‐Berezin, E., & Regnier, B. (1998) · Clinical Infectious Diseases · doi:10.1086/514938 · Cited by 66
Paterson, D. L. (2002) · Clinical Infectious Diseases · doi:10.1086/340532 · Cited by 65
Self-citationBaraniak, A., Sadowy, E., Hryniewicz, W., & Gniadkowski, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.1095-1097.2002 · Cited by 64
Brenwald, N. P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg051 · Cited by 64
Piperacillin/Tazobactam in the Treatment ofKlebsiella PneumoniaeInfections in Neonates
Pillay, T., Pillay, D. G., Adhikari, M., & Sturm, A. W. (1998) · American Journal of Perinatology · doi:10.1055/s-2007-993898 · Cited by 60
Segal‐Maurer, S., Mariano, N., Qavi, A., Urban, C. M., & Rahal, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/514754 · Cited by 60
Xiong, Z., Zhu, D., Wang, F., Zhang, Y., Okamoto, R., & Inoue, M. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00441-8 · Cited by 58
TZOUVELEKIS, L. S., & Bonomo, R. A. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230112183734 · Cited by 58
Self-citationFantin, B., Pangon, B., Potel, G., Caron, F., Vallee, E., Vallois, J. M., Mohler, J., Buré, A., Philippon, A., & Carbon, C. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.4.581 · Cited by 55
CTX-M extended-spectrum beta-lactamase arrives in the UK
Alobwede, I., M'Zali, F. H., Livermore, D. M., Heritage, J., Todd, N. J., & Hawkey, P. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg096 · Cited by 54
Martínez‐Aguilar, G., Alpuche-Aranda, C. M., Anaya, C., Alcántar-Curiel, M. D., Gayosso-Vázquez, C., Daza, C., Mijares, C., Tinoco, J. C., & Santos, J. I. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501855 · Cited by 54
Szabó, D., Filetoth, Z., Szentandrássy, J., Némedi, M., Tóth, E., Jeney, C., Kispál, G., & Rozgonyi, F. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.12.4167-4169.1999 · Cited by 54
CTX-M-14, a Plasmid-Mediated CTX-M Type Extended-Spectrum β-Lactamase Isolated from Escherichia coli
Ma, L., Ishii, Y., Chang, F., Yamaguchi, K., Ho, M., & Siu, L.-K. K. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1985-1988.2002 · Cited by 53
Yu, W. L., Winokur, P. L., Stein, D. L. V., Pfaller, M. A., Wang, J.-H., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1098-1100.2002 · Cited by 53
Borer, A., Moran‐Gilad, J., Menashe, G., Peled, N., Riesenberg, K., & Schlaeffer, F. (2002) · PubMed · Cited by 52
Schwaber, M. J., Raney, P. M., Rasheed, J. K., Biddle, J. W., Williams, P., McGowan, J. E., & Tenover, F. C. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.1.294-298.2004 · Cited by 52
Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type inKlebsiella pneumoniae,Taiwan
Yu, W. L., Pfaller, M. A., Winokur, P. L., & Jones, R. N. (2002) · Emerging infectious diseases · doi:10.3201/eid0805.010346 · Cited by 49
Holländer, R., Ebke, M., Barck, H., & von Pritzbuer, E. (2001) · Journal of Hospital Infection · doi:10.1053/jhin.2001.0997 · Cited by 48
Sader, H., Gales, A. C., Td, G., Ma, P., & Jones, R. N. (2000) · PubMed · Cited by 47
Gonzalez-Vertiz, A., Alcántar-Curiel, M. D., Cuauhtli, M., Daza, C., Gayosso-Vázquez, C., Solache, G., Horta, C., Mejia, F., Santos, J. I., & Alpuche-Aranda, C. M. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501854 · Cited by 44
Gazouli, M., Sv, S., Tzelepi, Ε., Козлова, Н. С., Гладин, Д. П., & TZOUVELEKIS, L. S. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.1.119 · Cited by 42
Yu, W., Jones, R. N., Hollis, R. J., Messer, S. A., Biedenbach, D. J., Deshpande, L. M., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.12.4666-4669.2002 · Cited by 37
TEM-121, a Novel Complex Mutant of TEM-Type β-Lactamase from Enterobacter aerogenes
Poirel, L., Mammeri, H., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4528-4531.2004 · Cited by 36
Mendes, C., Hsiung, A., Kiffer, C. R. V., Oplustil, C. P., Sinto, S. I., Mimica, I., & Zoccoli, C. M. (2000) · PubMed · Cited by 33
Hageman, J. C., Fridkin, S. K., Mohammed, J. M., Steward, C. D., Gaynes, R. P., & Tenover, F. C. (2003) · Infection Control and Hospital Epidemiology · doi:10.1086/502214 · Cited by 32
Weldhagen, G. F., & Prinsloo, A. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.12.012 · Cited by 31
Sanders, C. C. (1996) · PubMed · Cited by 29
Neuwirth, C., Madec, S., Siébor, E., Péchinot, A., Duez, J.-M., Pruneaux, M., Fouchereau‐Péron, M., Kazmierczak, A., & Labia, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3591-3594.2001 · Cited by 28
Gierczyński, R., Szych, J., Cieślik, A., Rastawicki, W., & Jagielski, M. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00044-x · Cited by 25
Aktaş, E., Yiğit, N., Yazgı, H., & Ayyıldız, A. (2002) · Journal of International Medical Research · doi:10.1177/147323000203000414 · Cited by 22
Comparison of Five Different Methods for Detection of SHV Extended-Spectrum β-Lactamases
Bedenić, B., Randegger, C. C., Boras, A., et al. (2001) · Journal of Chemotherapy · doi:10.1179/joc.2001.13.1.24 · Cited by 16
Analysis of the bla toho Gene Coding for Toho-2-β-Lactamase
Labia, R. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.10.2576 · Cited by 16
Shen, D., Winokur, P. L., & Jones, R. N. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00351-x · Cited by 15
Weldhagen, G. F. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3402-3406.2004 · Cited by 15
Shipton, S. E., Cotton, M. F., Wessels, G., & Wasserman, E. (2001) · PubMed · Cited by 8
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
Klein, E. Y., Van Boeckel, T. P., Martinez, E. M., Pant, S., Gandra, S., Levin, S. A., Goossens, H., & Laxminarayan, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717295115 · Cited by 3,232
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Metadata
- Authors
- Paterson, D. L., & Bonomo, R. A.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2005-10
- Volume
- 18
- Issue
- 4
- Pages
- 657-686
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2131946678
- Cited by
- 3,491
- References
- 235
- FWCI
- 43.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.